Sage Journals: Discover world-class research

Abstract

Alternative combinations of antiretrovirals (ARVs) are desired to increase treatment options for HIV-infected patients. PROGRESS was a randomized, open-label, 96-week pilot study comparing a regimen of lopinavir/ritonavir (LPV/r) 400/100 mg twice daily in combination with either raltegravir (RAL) 400 mg twice daily or tenofovir/emtricitabine (TDF/FTC) 300/200 mg once daily in ARV-naive adults. A total of 206 subjects were randomized and treated (LPV/r+RAL, N=101; LPV/r+TDF/FTC, N=105). Demographics and baseline characteristics were similar across treatment groups. At 96 weeks, 66.3% of subjects receiving LPV/r+RAL and 68.6% of subjects receiving LPV/r+TDF/FTC were responders (plasma HIV-1 RNA levels<40 copies/ml) by the FDA time to loss of virologic response (FDA-TLOVR) algorithm (p=0.767). Mean CD4⁺ T cell increases through 96 weeks were similar between treatment groups (LPV/r+RAL=281 cells/mm³, LPV/r+TDF/FTC=296 cells/mm³, p=0.598). Safety and tolerability were generally similar between groups. The LPV/r+RAL regimen resulted in greater increases in peripheral fat, but not trunk fat, compared with LPV/r+TDF/FTC. There was a statistically significantly greater mean reduction in estimated glomerular filtration rate from baseline to week 96 in the LPV/r+TDF/FTC group compared with the LPV/r+RAL group (−7.33 ml/min vs. −1.43 ml/min; p=0.035). The LPV/r+TDF/FTC group had a statistically significant (p<0.001) mean percent decrease from baseline to week 96 in bone mineral density, which was significantly different from the mean percent change in the LPV/r+RAL group (–2.48% vs. +0.68%, p<0.001). These efficacy and safety observations support further evaluation of the LPV/r+RAL regimen.

Get full access to this article

View all access options for this article.

References

Panel on Antiretroviral Guidelines for Adults Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults, adolescents. Department of Health and Human Services, March 12, 2012; 1–240. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. 2012 June 10.

Gathe

, Silva

, Cohen

et al. A once-daily lopinavir/ritonavir-based regimen is noninferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks. J Acquir Immune Defic Syndr, 2009; 50,5:474–481.

Zajdenverg

, Podsadecki

, Badal-Faesen

et al. Similar safety and efficacy of once- and twice-daily lopinavir/ritonavir tablets in treatment-experienced HIV-1-infected subjects at 48 weeks. J Acquir Immune Defic Syndr, 2010; 54,2:143–151.

Walmsley

, Bernstein

, King

et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med, 2002; 346,26:2039–2046.

Palmer

, Maldarelli

, Wiegand

et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci USA, 2008; 105,10:3879–3884.

Lennox

, DeJesus

, Lazzarin

et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet, 2009; 374,9692:796–806.

Reynes

, Lawal

, Pulido

et al. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: The progress study, 48-week results. HIV Clin Trials, 2011; 12,5:255–267.

Johnson

, Brun-Vezinet

, Clotet

et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med, 2010; 18,5:156–163.

Gonzalez-Garcia

, Cohen

, Johnson

et al. Comparable safety and efficacy with once-daily versus twice-daily dosing of lopinavir/ritonavir tablets with emtricitabine+tenofovir DF in antiretroviral-naive, HIV type 1-infected subjects: 96 week final results of the randomized trial M05-730. AIDS Res Hum Retroviruses, 2010; 26,8:841–845.

10.

Lennox

, Dejesus

, Berger

et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr, 2010; 55,1:39–48.

11.

Mocroft

, Kirk

, Reiss

et al. Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients. AIDS, 2010; 24,11:1667–1678.

12.

Moreno

, Miralles

, Negredo

et al. Disorders of body fat distribution in HIV-1-infected patients. AIDS Rev, 2009; 11,3:126–134.

13.

Moyle

, Yang

, Wirtz

et al. Body composition changes in treatment-naive patients treated with boosted PIs plus TDF/FTC: Results from the CASTLE Study through 96 weeks. [LBPS11/6] 12th European AIDS Conference, November 11–14, 2009, Cologne, Germany.

14.

Young

, Dao

, Buchacz

, Baker

, Brooks

. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis, 2011; 52,8:1061–1068.

15.

Stellbrink

, Orkin

, Arribas

et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis, 2010; 51,8:963–972.

16.

McComsey

, Kitch

, Daar

et al.

Bone, limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: A prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [106LB]

17th Conference on Retroviruses and Opportunistic Infections, February 16–19, 2010, San Francisco, CA.

17.

Gutierrez

, Masia

. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev, 2011; 13,2:109–118.

18.

Piso

, Rothen

, Stahl

. Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr, 2011; 56,4:320–324.

19.

Kozal

, Lupo

, Dejesus

et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results. HIV Clin Trials, 2012; 13,3:119–130.

20.

Taiwo

, Zheng

, Gallien

et al.

Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

AIDS, 2011; 25,17:2113–2122.

21.

Gardner

, Melendez

, Astiz

, Bray

. Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase. J Int Assoc Physicians AIDS Care (Chic), 2012; 11,1:34–39.

22.

Gardner

, Sharma

, Peng

et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS, 2008; 22,1:75–82.

23.

Gardner

, Hullsiek

, Telzak

et al. Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS, 2010; 24,3:395–403.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

Lopinavir/Ritonavir Combined with Raltegravir or Tenofovir/Emtricitabine in Antiretroviral-Naive Subjects: 96-Week Results of the PROGRESS Study

Abstract

Get full access to this article

References

Supplementary Material